486 related articles for article (PubMed ID: 25200104)
21. CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice.
Wagner M; Halilbasic E; Marschall HU; Zollner G; Fickert P; Langner C; Zatloukal K; Denk H; Trauner M
Hepatology; 2005 Aug; 42(2):420-30. PubMed ID: 15986414
[TBL] [Abstract][Full Text] [Related]
22. Hesperidin alleviates cholestasis via activation of the farnesoid X receptor in vitro and in vivo.
Zhang G; Sun X; Wen Y; Shi A; Zhang J; Wei Y; Wu X
Eur J Pharmacol; 2020 Oct; 885():173498. PubMed ID: 32841642
[TBL] [Abstract][Full Text] [Related]
23. Farnesoid X receptor agonists in biliary tract disease.
Fiorucci S; Baldelli F
Curr Opin Gastroenterol; 2009 May; 25(3):252-9. PubMed ID: 19300246
[TBL] [Abstract][Full Text] [Related]
24. Beneficial effects of bile acid receptor agonists in pulmonary disease models.
Comeglio P; Morelli A; Adorini L; Maggi M; Vignozzi L
Expert Opin Investig Drugs; 2017 Nov; 26(11):1215-1228. PubMed ID: 28949776
[TBL] [Abstract][Full Text] [Related]
25. FXR-dependent Rubicon induction impairs autophagy in models of human cholestasis.
Panzitt K; Jungwirth E; Krones E; Lee JM; Pollheimer M; Thallinger GG; Kolb-Lenz D; Xiao R; Thorell A; Trauner M; Fickert P; Marschall HU; Moore DD; Wagner M
J Hepatol; 2020 Jun; 72(6):1122-1131. PubMed ID: 32001325
[TBL] [Abstract][Full Text] [Related]
26. Targeting farnesoid X receptor for liver and metabolic disorders.
Fiorucci S; Rizzo G; Donini A; Distrutti E; Santucci L
Trends Mol Med; 2007 Jul; 13(7):298-309. PubMed ID: 17588816
[TBL] [Abstract][Full Text] [Related]
27. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor.
Pineda Torra I; Claudel T; Duval C; Kosykh V; Fruchart JC; Staels B
Mol Endocrinol; 2003 Feb; 17(2):259-72. PubMed ID: 12554753
[TBL] [Abstract][Full Text] [Related]
28. Investigational farnesoid X receptor agonists for the treatment of primary biliary cholangitis.
Akepati PR; Gochanour EM
Expert Opin Investig Drugs; 2024 Jun; 33(6):627-638. PubMed ID: 38676426
[TBL] [Abstract][Full Text] [Related]
29. Farnesoid X receptor agonists for primary biliary cirrhosis.
Lindor KD
Curr Opin Gastroenterol; 2011 May; 27(3):285-8. PubMed ID: 21297469
[TBL] [Abstract][Full Text] [Related]
30. Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease.
Wu W; Zhu B; Peng X; Zhou M; Jia D; Gu J
Biochem Biophys Res Commun; 2014 Jan; 443(1):68-73. PubMed ID: 24269813
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors.
D'Amore C; Di Leva FS; Sepe V; Renga B; Del Gaudio C; D'Auria MV; Zampella A; Fiorucci S; Limongelli V
J Med Chem; 2014 Feb; 57(3):937-54. PubMed ID: 24387325
[TBL] [Abstract][Full Text] [Related]
32. Role of FXR in regulating bile acid homeostasis and relevance for human diseases.
Rizzo G; Renga B; Mencarelli A; Pellicciari R; Fiorucci S
Curr Drug Targets Immune Endocr Metabol Disord; 2005 Sep; 5(3):289-303. PubMed ID: 16178789
[TBL] [Abstract][Full Text] [Related]
33. Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition.
Vaquero J; Monte MJ; Dominguez M; Muntané J; Marin JJ
Biochem Pharmacol; 2013 Oct; 86(7):926-39. PubMed ID: 23928191
[TBL] [Abstract][Full Text] [Related]
34. Novel Aspects in the Management of Cholestatic Liver Diseases.
Chazouillères O
Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
[TBL] [Abstract][Full Text] [Related]
35. Unaltered Liver Regeneration in Post-Cholestatic Rats Treated with the FXR Agonist Obeticholic Acid.
de Haan LR; Verheij J; van Golen RF; Horneffer-van der Sluis V; Lewis MR; Beuers UHW; van Gulik TM; Olde Damink SWM; Schaap FG; Heger M; Olthof PB
Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33578971
[No Abstract] [Full Text] [Related]
36. Positive regulation of osteogenesis by bile acid through FXR.
Cho SW; An JH; Park H; Yang JY; Choi HJ; Kim SW; Park YJ; Kim SY; Yim M; Baek WY; Kim JE; Shin CS
J Bone Miner Res; 2013 Oct; 28(10):2109-21. PubMed ID: 23609136
[TBL] [Abstract][Full Text] [Related]
37. Alpha-naphthylisothiocyanate impairs bile acid homeostasis through AMPK-FXR pathways in rat primary hepatocytes.
Li X; Liu R; Yu L; Yuan Z; Sun R; Yang H; Zhang L; Jiang Z
Toxicology; 2016 Aug; 370():106-115. PubMed ID: 27702592
[TBL] [Abstract][Full Text] [Related]
38. The Pharmacology of Bile Acids and Their Receptors.
Fiorucci S; Distrutti E
Handb Exp Pharmacol; 2019; 256():3-18. PubMed ID: 31201555
[TBL] [Abstract][Full Text] [Related]
39. Investigation on bile acid receptor regulators. Discovery of cholanoic acid derivatives with dual G-protein coupled bile acid receptor 1 (GPBAR1) antagonistic and farnesoid X receptor (FXR) modulatory activity.
Sepe V; Renga B; Festa C; Finamore C; Masullo D; Carino A; Cipriani S; Distrutti E; Fiorucci S; Zampella A
Steroids; 2016 Jan; 105():59-67. PubMed ID: 26607331
[TBL] [Abstract][Full Text] [Related]
40. FXR and PXR: potential therapeutic targets in cholestasis.
Jonker JW; Liddle C; Downes M
J Steroid Biochem Mol Biol; 2012 Jul; 130(3-5):147-58. PubMed ID: 21801835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
